Statistical Analysis of Cost‐effectiveness Data
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; none of the 1 sources its claims cite is checked for support yet.
Abstract
Preface. 1. Concepts. 1.1 Introduction. 1.2 Cost-effectiveness data and the parameters of interest. 1.3 The cost-effectiveness plane, the ICER and INB. 1.4 Outline. 2. Parameter Estimation for Non-censored Data. 2.1 Introduction. 2.2 Cost. 2.3 Effectiveness. 2.4 Summary. 3. Parameter Estimation for Censored Data. 3.1 Introduction. 3.2 Mean Cost. 3.3 Effectiveness. 3.4 Summary. 4. Cost-effectiveness Analysis. 4.1 Introduction. 4.2 Incremental cost-effectiveness ratio. 4.3 Incremental net benefit. 4.4 The cost-effectiveness acceptability curve. 4.5 Using bootstrap methods. 4.6 A Bayesian incremental net benefit approach. 4.7 Kinked thresholds. 4.8 Summary. 5. Cost-effectiveness Analysis: Examples. 5.1 Introduction. 5.2 The CADET-Hp trial. 5.3 Symptomatic hormone-resistant prostate cancer. 5.4 The Canadian implantable defibrillator study (CIDS). 5.5 The EVALUATE trial. 5.6 Bayesian approach applied to the UK PDS study. 5.7 Summary. 6. Power and Sample Size Determination. 6.1 Introduction. 6.2 Approaches based on the cost-effectiveness plane. 6.3 The classical approach based on net benefit. 6.4 Bayesian take on the classical approach. 6.5 The value of information approach. 6.6 Summary. 7. Covariate Adjustment and Sub-group Analysis. 7.1 Introduction. 7.2 Non-censored data. 7.3 Censored data. 7.4 Summary. 8. Multicenter and Multinational Trials. 8.1 Introduction. 8.2 Background to multinational cost-effectiveness. 8.3 Fixed effect approaches. 8.4 Random effects approaches. 8.5 Summary. 9. Modeling Cost-effectiveness. 9.1 Introduction. 9.2 A general framework for modeling cost-effectiveness results. 9.3 Case study: an economic appraisal of the goal study. 9.4 Summary. References. Author Index. Subject Index. Series List.
Overview
CoChat Summary
TL;DR
Willan and Briggs’s book is described as a thorough, authoritative guide to the statistical analysis of cost and effectiveness data collected alongside clinical trials. It covers core estimation, confidence intervals, skewed and censored data, then moves to power/sample size, covariate adjustment, multinational trials, and indirect estimation of ICER.
Key findings
- The book has 9 chapters; the first five are described as the core, giving a self-contained treatment of basic CEA concepts and methods for estimating the mean, variance, and covariance of costs and effectiveness, plus the mean incremental cost-effectiveness ratio (ICER) and mean incremental net benefits (INB) and their confidence intervals.
- The core chapters also address skewed and censored data and include several worked examples illustrating the methods developed.
- The remaining chapters cover more specialized issues including power and sample size determination, using baseline covariates to adjust for confounding, multilevel and multinational trials, and statistical modeling for indirectly estimating ICER.
- The reviewer says the book is “thorough and authoritative,” “well written and very useful,” and an “immensely valuable up-to-date guide” for the literature on CEA data analysis.
Methods
- This is a book review, not an empirical study.
- The text reviewed is a 9-chapter book focused on statistical methods for cost and effectiveness data collected alongside clinical trials.
- The review summarizes the book’s treatment of estimation, confidence intervals, skewed/censored data, power/sample size, covariate adjustment, multinational trials, and indirect ICER estimation.
Limitations
- The authors “could have made their book more readable” and broadened its audience by changing the style of presentation and including other topics.
- The review says the book is not exhaustive for a growing field; it does not cover probabilistic sensitivity analysis of cost-effectiveness models and omits some issues such as specification and measurement errors, heteroscedasticity, and autocorrelation.
- Evident from the review: the treatment is specialized, and the book is aimed mainly at readers with interest or background in CEA/statistics rather than a general audience.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 1 Not checked · 6 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These chapters also discuss methods for dealing with such issues as skewed and censored data and provide several examples illustrating the methods developed.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Their book is a thorough and authoritative exposition of the subject that can serve as an immensely valuable up-to-date guide to the literature on the statistical analysis of cost and effectiveness data collected alongside clinical trials.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The first five chapters, arguably the core of the book, provide a self-contained presentation of the basic concepts of CEA and the statistical methods for estimating key statistics, such as the mean, variance, and covariance of costs and effectiveness, as well as the mean incremental cost-effectiveness ratio (ICER) and the mean incremental net benefits (INB), and their corresponding confidence intervals.”
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonetheless, the authors could have made their book more readable and garner a larger audience by making some changes to their style of presentation and including other topics.”
In the paper
“Although the book does require prerequisite reading on Bayesian methods (perhaps Gelman, Carlin, Stern, and Rubin 2003), this book should be required reading for all graduate students of statistics, statistical researchers in this field, and students and researchers in other fields that use these technologies.”
What the sources say
- Not checked yetcites Gelman, Carlin, Stern, and Rubin 2003 source
4 more claims
Create a free account to see all 9 claims and to verify the 1 reference still open.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Better Bootstrap Confidence Intervals
Efron, B. (1987) · Journal of the American Statistical Association · doi:10.1080/01621459.1987.10478410 · Cited by 3,364 · cited 1×
“Efron and Tibshirani (1993) suggest that the ‘ideal’ bootstrap estimate corresponds to an infinite number of bootstrap re-samples.”
BackgroundSmearing Estimate: A Nonparametric Retransformation Method
Duan, N. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10478017 · Cited by 2,232 · cited 1×
“2 A non-parametric ‘smearing’ estimator While the Taylor series approximation may be adequate, there is an alternative approach known as non-parametric smearing that does not require a specific distribution for the error term, see Duan (1983). Note that the expectation of the untransformed cost can be written as a fun…”
BackgroundThe Importance of the Normality Assumption in Large Public Health Data Sets
Lumley, T., Diehr, P., Emerson, S., & Chen, L. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140546 · Cited by 1,803
Laupacis, A., Feeny, D. H., Detsky, A. S., & Tugwell, P. (1992) · Europe PMC (PubMed Central) · Cited by 1,719
Connolly, S. J., Gent, M., Roberts, R. S., Dorian, P., Roy, D., Sheldon, R. S., Mitchell, L. B., Green, M. S., Klein, G. J., & O’Brien, B. (2000) · Circulation · doi:10.1161/01.cir.101.11.1297 · Cited by 1,607 · cited 2×
“The clinical results are reported in Connolly et al. (2000), and the economic evaluation in O’Brien et al. (2000). For this example the measure of effectiveness is survival time, with the duration of interest set to 6.”
BackgroundBootstrapping: A Nonparametric Approach to Statistical Inference.
AA, Mooney, C. Z., & Duval, R. D. (1994) · Journal of the American Statistical Association · doi:10.2307/2290969 · Cited by 1,351
Utility approach to measuring health-related quality of life
Torrance, G. W. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90019-1 · Cited by 1,072 · cited 1×
“52 Cost-effectiveness analysis acceptability curve (CEAC) can provide a more flexible and a natural means for expressing the uncertainty of parameter estimators, see van Hout et al. (1994), Briggs and Fenn (1998) and Briggs (1999).”
BackgroundManca, A., Hawkins, N., & Sculpher, M. J. (2005) · Health Economics · doi:10.1002/hec.944 · Cited by 1,024 · cited 1×
“Manca et al. (2005a) discuss the baseline adjustment of QALYs in particular and present simulation results to show that regression adjustment outperforms simple measures of change from baseline, which is sometimes used as a method for adjusting for baseline imbalance in the outcome of interest.”
Method
Research works printed but not linked: 3
- Barlow, R., Bartholomew, D., Bremner, J., and Brunk, H. (1972), Statistical Inference Under Order Restrictions , New York: Wiley.
- Robertson, T., Wright, F. T., and Dykstra, R. (1988), Order-Restricted Statistical Inference , New York: Wiley.
- Silvapulle, M., and Sen, P. K. (2004), Constrained Statistical Inference , New York: Wiley.
Cited by
Health-related quality of life measured using the EQ-5D–5L: South Australian population norms
McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0537-0 · Cited by 472
Statistical Issues in Drug Development
Senn, S. (2021) · Wiley eBooks · doi:10.1002/9781119238614 · Cited by 384
A Practical Guide to Value of Information Analysis
Wilson, E. C. F. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0219-x · Cited by 159
Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials
Gomes, M., Ng, E. S.-W., Grieve, R., Nixon, R., Carpenter, J., & Thompson, S. G. (2012) · Medical Decision Making · doi:10.1177/0272989x11418372 · Cited by 151
Hartman, E., Grieve, R., Ramsahai, R., & Sekhon, J. S. (2015) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/rssa.12094 · Cited by 149
“…the relative effectiveness and cost-effectiveness of interventions for target populations that usually differ from those represented by RCT participants (Hoch et al., 2002; Mitra and Indurkhya, 2005; Mojtabai and Zivin, 2003; Nixon and Thompson, 2005; Willan et al., 2004; Willan and Briggs, 2006).”
BackgroundProbabilistic sensitivity analysis in health economics
Baio, G., & Dawid, A. P. (2011) · Statistical Methods in Medical Research · doi:10.1177/0962280211419832 · Cited by 174
Mittmann, N., Au, H., Tu, D., O'Callaghan, C. J., Isogai, P. K., Karapetis, C. S., Zalcberg, J. R., Evans, W. K., Moore, M. J., Siddiqui, J., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp232 · Cited by 144
The impact of severe haemophilia and the presence of target joints on health-related quality-of-life
O'Hara, J., Walsh, S., Camp, C., Mazza, G., Carroll, L., Hoxer, C., & Wilkinson, L. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0908-9 · Cited by 117
An 8-step framework for implementing time-driven activity-based costing in healthcare studies
Etges, A. P. B. D. S., Cruz, L. N., Kuhmmer, R., Neyeloff, J. L., Schlatter, R. P., Astigarraga, C. C., Falavigna, M., & Polanczyk, C. A. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01085-8 · Cited by 141
Stanley, R. M., Jones, R. A., Cliff, D. P., Trost, S. G., Berthelsen, D., Salmon, J., Batterham, M., Eckermann, S., Reilly, J. J., Brown, N., et al. (2016) · BMC Public Health · doi:10.1186/s12889-016-3743-0 · Cited by 124
Confidence interval estimation for lognormal data with application to health economics
Zou, G., Taleban, J., & Huo, C. Y. (2009) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2009.03.016 · Cited by 126
McCarthy, I., O’Brien, M. F., Ames, C. P., Robinson, C., Errico, T. J., Polly, D. W., & Hostin, R. A. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.3.focus1415 · Cited by 105
Optimal clinical trial design using value of information methods with imperfect implementation
Willan, A. R., & Eckermann, S. (2010) · Health Economics · doi:10.1002/hec.1493 · Cited by 97
“Statistical methods for the analysis of data from cost-effectiveness trials have undergone rapid development over the past ten years (Willan and Briggs, 2006).”
MethodSelf-citationHiggins, A. M., & Harris, A. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2011.10.002 · Cited by 98
Michalowsky, B., Xie, F., Eichler, T., Hertel, J., Kaczynski, A., Kilimann, I., Teipel, S., Wucherer, D., Zwingmann, I., Thyrian, J. R., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.008 · Cited by 89
Handorf, E. A., McElligott, S. C., Vachani, A., Langer, C. J., Bristol, M. N., Armstrong, K., & Asch, D. A. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000502 · Cited by 88
Hoomans, T., Fenwick, E. A. L., Palmer, S., & Claxton, K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00431.x · Cited by 93
Bradbury, P. A., Tu, D., Seymour, L., Isogai, P. K., Zhu, L., Ng, R., Mittmann, N., Tsao, M., Evans, W. K., Shepherd, F. A., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp518 · Cited by 77
Impact of housing on the survival of persons with AIDS
Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Vu, A., Bamberger, J. D., & Katz, M. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-220 · Cited by 73
Moran, G. S., Kalha, J., Mueller‐Stierlin, A. S., Kilian, R., Krumm, S., Slade, M., Charles, A., Mahlke, C., Nixdorf, R., Basangwa, D., et al. (2020) · Trials · doi:10.1186/s13063-020-4177-7 · Cited by 80
Estimates of the Cost-Effectiveness of Pediatric Bilateral Cochlear Implantation
Summerfield, A. Q., Lovett, R. E. S., Bellenger, H., & Batten, G. (2010) · Ear and Hearing · doi:10.1097/aud.0b013e3181de40cd · Cited by 64
Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies
Ara, R., & Wailoo, A. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.003 · Cited by 62
Gomes, M., Grieve, R., Nixon, R., & Edmunds, W. J. (2012) · Medical Decision Making · doi:10.1177/0272989x11407341 · Cited by 60
Willan, A. R. (2008) · Clinical Trials · doi:10.1177/1740774508098413 · Cited by 59
Self-citationCannizzo, S., Lorenzoni, V., Palla, I., Pirri, S., Trieste, L., Triulzi, I., & Turchetti, G. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000794 · Cited by 58
Grieve, R., Nixon, R. M., & Thompson, S. G. (2009) · Medical Decision Making · doi:10.1177/0272989x09341752 · Cited by 57
Globally optimal trial design for local decision making
Eckermann, S. D., & Willan, A. R. (2008) · Health Economics · doi:10.1002/hec.1353 · Cited by 55
Self-citationMakai, P., Looman, W., Adang, E., Melis, R. J. F., Stolk, E. A., & Fabbricotti, I. N. (2014) · The European Journal of Health Economics · doi:10.1007/s10198-014-0583-7 · Cited by 59
MacNeil Vroomen, J., Eekhout, I., Dijkgraaf, M. G., van Hout, H., de Rooij, S. E., Heymans, M. W., & Bosmans, J. E. (2016) · The European Journal of Health Economics · doi:10.1007/s10198-015-0734-5 · Cited by 52
NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models
Ara, R., & Wailoo, A. (2011) · Europe PMC (PubMed Central) · Cited by 78
Digital interventions in mental health: Evidence syntheses and economic modelling
Gega, L., Jankovic, D., Saramago, P., Marshall, D., Dawson, S., Brabyn, S., Nikolaidis, G. F., Melton, H., Churchill, R., & Bojke, L. (2022) · Health Technology Assessment · doi:10.3310/rcti6942 · Cited by 48
Cost-Effectiveness Analysis: A Proposal of New Reporting Standards in Statistical Analysis
Bang, H., & Zhao, H. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.860157 · Cited by 58
“Different quadrants represent different preferences for a new vs. standard treatment (Hoch et al., 2002; Obenchain, 1999; Willan and Briggs, 2006); readers may refer to “5 Decision Regions” described in Appendix A that could aid interpretation (Laupacis et al., 1992; Obenchain, 1999).”
BackgroundParra-López, C., Groot, J. C. J., Carmona‐Torres, C., & Rossing, W. A. H. (2009) · Land Use Policy · doi:10.1016/j.landusepol.2008.12.006 · Cited by 49
Wan, X., Peng, L., & Li, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121353 · Cited by 58
MacNeil Vroomen, J., Bosmans, J. E., Eekhout, I., Joling, K. J., van Mierlo, L. D., Meiland, F. J. M., van Hout, H. P. J., & de Rooij, S. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160908 · Cited by 48
Willan, A. R., & Kowgier, M. E. (2008) · Clinical Trials · doi:10.1177/1740774508093981 · Cited by 48
Self-citationWatson, J., Crosby, H., Dale, V., Tober, G., Wu, Q., Lang, J., McGovern, R., Newbury-Birch, D., Parrott, S., Bland, J., et al. (2013) · Health Technol Assess · doi:10.3310/hta17250 · Cited by 47
Statistical analysis of cost–effectiveness data from randomized clinical trials
Willan, A. R. (2006) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.6.3.337 · Cited by 47
Self-citationDunlop, W., Uhl, R., Khan, I., Taylor, A., & Barton, G. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.665279 · Cited by 48
Gomes, M., Díaz-Ordaz, K., Grieve, R., & Kenward, M. G. (2013) · Medical Decision Making · doi:10.1177/0272989x13492203 · Cited by 46
van Vliet, E. P. M., Steyerberg, E. W., Eijkemans, M. J. C., Kuipers, E. J., & Siersema, P. D. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603960 · Cited by 46
“Extra diagnostic evaluations can hence not be very cost-effective, although no formal analysis of uncertainty was performed (bootstrapping, or construction of acceptability curves) (Willan and Briggs, 2006).”
Large Sample Inference about the Ratio of Means in Two Independent Populations
Mahmoudi, M. R., Behboodian, J., & Maleki, M. (2017) · Journal of Statistical Theory and Applications · doi:10.2991/jsta.2017.16.3.8 · Cited by 44
Dakin, H., & Gray, A. M. (2017) · Statistics in Medicine · doi:10.1002/sim.7322 · Cited by 44
Heath, A., Manolopoulou, I., & Baio, G. (2016) · Statistics in Medicine · doi:10.1002/sim.6983 · Cited by 43
GAMMA SHAPE MIXTURES FOR HEAVY-TAILED DISTRIBUTIONS
Venturini, S., Dominici, F., & Parmigiani, G. (2006) · Collection of Biostatistics Research Archive · Cited by 39
Shiroiwa, T., Fukuda, T., & Tsutani, K. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605114 · Cited by 38
Vuong, D. A., Rades, D., van Eck, A. T. C. J., Horstmann, G. A., & Busse, R. (2012) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.05.005 · Cited by 38
COACH consortium, Lunkenheimer, F., Domhardt, M., Geirhos, A., Kilian, R., Mueller-Stierlin, A. S., Holl, R. W., Meissner, T., Minden, K., Moshagen, M., et al. (2020) · Trials · doi:10.1186/s13063-019-4041-9 · Cited by 37
Weber, J., Angerer, P., Brenner, L., Brezinski, J., Chrysanthou, S., Erim, Y., Feißt, M., Hansmann, M., Hondong, S., Kessemeier, F. M., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-11195-9 · Cited by 39
Grieve, R., Sekhon, J. S., Hu, T., & Bloom, J. R. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00834.x · Cited by 36
“A key issue in CEA is to combine costs and outcomes in a way that can appropriately recognize the statistical uncertainty surrounding estimates of cost-effectiveness (Willan and Briggs 2006).”
BackgroundA Study on Confidence Intervals for Incremental Cost‐Effectiveness Ratios
Wang, H., & Zhao, H. (2008) · Biometrical Journal · doi:10.1002/bimj.200810439 · Cited by 36
“There have been several measures proposed and evaluated for cost-effectiveness analysis in the literature (Chaudhary and Sterns, 1996; Willan and Lin, 2001; Heitjan, 2000; Briggs, O’Brien, and Blackhouse, 2002; O’Brien and Briggs, 2002; Willan and Briggs, 2006).”
Mannino, I., Franco, D., Piccioni, E., Favero, L., Mattiuzzo, E., & Zanetto, G. (2007) · Environmental Management · doi:10.1007/s00267-007-9001-6 · Cited by 36
“90 When there are difficulties in assigning a monetary value to the benefits, a cost- 91 effectiveness analysis can be used (Gudger and Barker, 1993; Hanley and Spash 92 1993; Anderson, 1998; Wheeler, 1998; Heinzerling and Ackerman, 2002; OECD, 93 2006; Willan and Briggs, 2006).”
MethodBernstein, S. L., Dziura, J., Weiss, J., Miller, T., Vickerman, K. A., Grau, L. E., Pantalon, M. V., Abroms, L., Collins, L. M., & Toll, B. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.12.016 · Cited by 35
Average Cost-Effectiveness Ratio with Censored Data
Bang, H., & Zhao, H. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.544437 · Cited by 48
Lazzaro, C. R., Bianchi, C., Peracino, L., Zacchetti, P., & Uccelli, A. (2009) · Neurological Sciences · doi:10.1007/s10072-009-0015-0 · Cited by 34
Eckermann, S., & Coelli, T. (2013) · Social Science & Medicine (1967) · doi:10.1016/j.socscimed.2012.10.020 · Cited by 34
EQ-5D-5L Population Norms and Health Inequality in Colombia
Bailey, H. H., Janssen, M. F., Varela, R. O., & Moreno, J. A. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.12.002 · Cited by 32
Puts, M. T. E., Hsu, T., Mariano, C. J., Monette, J., Brennenstuhl, S., Pitters, E., Ray, J., Wan-Chow-Wah, D., Kozlowski, N., Krzyzanowska, M. K., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024485 · Cited by 32
Brühmann, B. A., Reese, C., Kaier, K., Ott, M., Maurer, C., Kunert, S., Saurer, B. R., & Farin‐Glattacker, E. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4156-4 · Cited by 30
Lazzaro, C. R., Bordonaro, R., Cognetti, F., Fabi, A., Placido, S. D., Marchetti, Botticelli, A., Pronzato, P., Martelli, & Arpino, G. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s41850 · Cited by 30
Econometric approaches in evaluating costs and outcomes within pharmacoeconomic analyses
Skrepnek, G. H., Olvey, E. L., & Sahai, A. (2012) · Pharmaceuticals Policy and Law · doi:10.3233/ppl-2011-0345 · Cited by 29
“costs and outcomes associated with new technologies relative to various standards of care [2].”
BackgroundResultSample Size Determination for Cost-Effectiveness Trials
Willan, A. R. (2011) · PharmacoEconomics · doi:10.2165/11587130-000000000-00000 · Cited by 30
Self-citationRibbink, M. E., Vroomen, J. L. M., van Seben, R., Oudejans, I., & Buurman, B. M. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033802 · Cited by 28
Cheung, K., & Duan, N. (2014) · American Journal of Public Health · doi:10.2105/ajph.2013.301579 · Cited by 26
for the Canadian Bandaging Trial Group, Pham, B., Harrison, M. B., Chen, M. H., & Carley, M. E. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-346 · Cited by 25
Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology
Gabriel, S. E., Tugwell, P., & Drummond, M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.370 · Cited by 25
Nikelski, A., Keller, A., Schumacher‐Schönert, F., Dehl, T., Laufer, J., Sauerbrey, U., Wucherer, D., Dreier, A., Michalowsky, B., Zwingmann, I., et al. (2019) · Trials · doi:10.1186/s13063-019-3636-5 · Cited by 26
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs
Baio, G. (2013) · Statistics in Medicine · doi:10.1002/sim.6074 · Cited by 22
Pharmacoeconomics and Pharmacoepidemiology
Briggs, A. H., & Levy, A. R. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624110-00005 · Cited by 24
Self-citationMantopoulos, T., Mitchell, P. M., Welton, N. J., McManus, R. J., & Andronis, L. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0731-8 · Cited by 26
Kaskel, P., Tuschy, S., Wagner, A., Bannert, C., Cornely, O. A., Glasmacher, A. G., Lipp, H., & Ullmann, A. J. (2007) · Annals of Hematology · doi:10.1007/s00277-007-0382-7 · Cited by 22
QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets
Poteet, S., & Craig, B. M. (2021) · Patient · doi:10.1007/s40271-021-00509-z · Cited by 20
Cost-effectiveness of nutritional intervention on healing of pressure ulcers
Hisashige, A., & Ohura, T. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.04.013 · Cited by 29
A New Non-Parametric Matching Method for Bias Adjustment with Applications to Economic EvaluationsPreprint
Sekhon, J. S., & Grieve, R. (2007) · SSRN Electronic Journal · doi:10.2139/ssrn.1138926 · Cited by 24
“21 ‘PAC’ group compared with the ‘No PAC’ group different from 1; and is the incremental net monetary benefit (INB) positive (Glick et al., 2007; Willan and Briggs, 2006)?”
Lehmann, J., Schwarz, E., Azad, Z. R., Gritzka, S., Seifried-Dübon, T., Diebig, M., Gast, M., Kilian, R., Nater, U. M., Jarczok, M. N., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-10398-4 · Cited by 26
Cost-effectiveness of prevention strategies for American tegumentary leishmaniasis in Argentina
Orellano, P. W., Vázquez, N., & Salomón, O. D. (2013) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00172512 · Cited by 19
Soini, E. J. (2012) · The Open Complementary Medicine Journal · doi:10.2174/1876391x01204010001 · Cited by 19
Roth, J. A., Bensink, M. E., O’Donnell, P. V., Fuchs, E. J., Eapen, M., & Ramsey, S. D. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.95 · Cited by 18
Optimal healthcare decisions: Comparing medical treatments on a cost-effectiveness basis
Moreno, E., Girón, F. J., Polo, F. J. V., & Negrín, M. Á. (2009) · European Journal of Operational Research · doi:10.1016/j.ejor.2009.10.012 · Cited by 18
Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
Hisashige, A., Sasako, M., & Nakajima, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-443 · Cited by 19
Lazzaro, C. R., Barone, C. A., Caprioni, F., Cascinu, S., Falcone, A., Maiello, E., Milella, M., Pinto, C., Reni, M., & Tortora, G. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1464394 · Cited by 17
Bailey, H. H., Janssen, M. F., Foucade, A. L., Boodraj, G., Wharton, M., & Castillo, P. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01734-8 · Cited by 18
A doubly robust approach for cost–effectiveness estimation from observational data
Li, J., Vachani, A., Epstein, A. J., & Mitra, N. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217693262 · Cited by 20
Measuring the Value of Total Hip and Knee Arthroplasty: Considering Costs Over the Continuum of Care
Marshall, D. A., Wasylak, T., Khong, H., Parker, R. D., Faris, P., & Frank, C. (2011) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-011-2026-4 · Cited by 16
Marino, P., Siani, C., Roche, H. H., Protière, C., Fumoleau, P., Spielmann, M., Martin, A., Viens, P., & Corroller, A. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp561 · Cited by 16
Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer
Mar, J., Antón-Ladislao, A., Ibarrondo, O., Arrospide, A., Lázaro, S., González, N., Baré, M., Callejo, D., Redondo, M., Quintana, J. M., et al. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6250-9 · Cited by 15
“In addition, SUR analysis indicates the correlation between the parameters estimated for costs and QALYs and provides the estimation of the full variance–covariance matrix that allowed us to assess the uncertainty in ICER in terms of ellipse intervals [28] and obtain the values required to draw a cost-effectiveness pl…”
MethodInfluentialMichalowsky, B., Hoffmann, W. U., Kennedy, K., & Xie, F. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01166-z · Cited by 17
Acute medical unit comprehensive geriatric assessment intervention study (AMIGOS)
Edmans, J., Conroy, S., Harwood, R., Lewis, S., Elliott, R. A., Logan, P., Bradshaw, L. E., Franklin, M. K., & Gladman, J. R. F. (2011) · Trials · doi:10.1186/1745-6215-12-200 · Cited by 14
Wilson, S. M., Hair, L. P., Hertzberg, J. S., Kirby, A. C., Olsen, M. K., Lindquist, J. H., Maciejewski, M. L., Beckham, J. C., & Calhoun, P. S. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.08.008 · Cited by 14
Statistical considerations in economic evaluations: a guide for cardiologists
Reed, S. D. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu174 · Cited by 19
Campbell, D. A., Davies, J., & Wakerman, J. (2008) · Rural and Remote Health · doi:10.22605/rrh1010 · Cited by 14
Hisashige, A., Yoshida, S., & Kodaira, S. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604666 · Cited by 14
“The mean number of life-years and relapse-free life-years for patients in each group was estimated as the area under RFS and OS curves (Willan and Briggs, 2006).”
MethodBaio, G., & Russo, P. (2009) · PharmacoEconomics · doi:10.2165/11310250-000000000-00000 · Cited by 13
Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants
Eckermann, S. D. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0136-3 · Cited by 12
Chien, C., Hsia, T., & Chen, C. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12125 · Cited by 12
Gesundheitsökonomische Evaluation gemeindepsychiatrischer Interventionen
Kilian, R. (2012) · Der Nervenarzt · doi:10.1007/s00115-011-3469-2 · Cited by 10
Enhancing Value of Information Analyses
Janssen, M. P., & Koffijberg, H. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00548.x · Cited by 11
Sekhon, J. S., & Grieve, R. (2008) · SSRN Electronic Journal · doi:10.2139/ssrn.1301767 · Cited by 11
Oddershede, L., Riahi, S., Nielsen, J. C., Hjortshøj, S. P., Andersen, H., & Ehlers, L. H. (2014) · EP Europace · doi:10.1093/europace/eut384 · Cited by 9
Campioni, M., Agirrezabal, I., Hájek, R., Minařík, J., Pour, L., Spicka, I., Gonzalez‐McQuire, S., Jandová, P., & Maisnar, V. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01122-6 · Cited by 10
Metadata
- Authors
- Willan, A. R., & Briggs, A. H.
- Venue
- Wiley eBooks
- Publisher
- Wiley
- Published
- 2006-07-14
- OpenAlex
- W376156748
- Semantic Scholar
- 7d6360d70c621b9a8095d99d2074eceaf1d3839f
- Cited by
- 155
- References
- 53
- Citations by year
- 2021: 11 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 10 · 2016: 6 · 2015: 8 · 2014: 14 · 2013: 8 · 2012: 16
- FWCI
- 18.19
- Type
- book
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Wiley eBooks (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- cost-effectiveness analysis, incremental cost-effectiveness ratio, incremental net benefit, cost-effectiveness acceptability curves, censored data, bootstrapping, value of information, sample size and power, covariate adjustment, subgroup analysis, random effects models, economic evaluation, health technology assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-24 (prompt extract-v1).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.